Pair page
GHRP-2 with Sermorelin
Mechanism-tag overlap and published literature for GHRP-2 and Sermorelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrelin-receptor-agonistgrowth-hormone-secretagogue
ghrh-analog-growth-hormone-secretagogue
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying GHRP-2 and Sermorelin have published these mechanism-level observations. Not a co-administration recommendation.
1-29 fragment of GHRH; cleaner profile than CJC-1295 in some practitioner protocols. Combined with GHRP-2 for synergistic GH release.
Quick facts
GHRP-2
Sermorelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2001 | GHRP-2 | Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 1… PMID 11238504 | human study |
| 2005 | GHRP-2 | Granado M, Priego T, Martín AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288(3):E486-E492. PMID: 15507534. PMID 15507534 | preclinical, in vivo |
| 2004 | GHRP-2 | Doi N, Furukawa M, Sato C, Sasaki M, et al. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):857-867. PMID: 15646370. (Foundational pharmacology characterization by Kaken.) PMID 15646370 | mechanism / discovery |
| 1999 | GHRP-2 | Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470. (Ghrelin discovery — endogenous ligand.) PMID 10604470 | mechanism / discovery |
| 1996 | GHRP-2 | Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID: 8688086. (GHS-R1a cloning.) PMID 8688086 | mechanism / discovery |
| 2017 | GHRP-2 | Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Medicc Rev. 2017. PMC5392015. (Class review of cytoprotective evidence.) | review |
| 2026 | GHRP-2 | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (GHRP family banned under S2.) | regulatory / registry |
| 2025 | GHRP-2 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026. | regulatory / registry |
| — | GHRP-2 | Thomas A, Höppner S, Geyer H, et al. Determination of growth hormone-releasing peptides in serum by LC-MS/MS for sports drug testing. (WADA detection methodology applicable to GHRP-2.) | regulatory / registry |
| 2004 | GHRP-2 | Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-880. PMID: 15646371. (Safety pharmacology evaluation.) PMID 15646371 | research article |
| 2004 | GHRP-2 | Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP 102, WAY GPA 748. Drugs R D. 2004;5(4):236-239. PMID: 15230633. (Drug development profile.) PMID 15230633 | research article |
| 2001 | GHRP-2 | Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-1469. PMID: 11297568. PMID 11297568 | research article |
| 2012 | Sermorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 1999 | Sermorelin | Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID: 18031173. PMID 18031173 | human study |
| 1996 | Sermorelin | Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134(3):352-356. PMID: 8616536. PMID 8616536 | human study |
| 2020 | Sermorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 2025 | Sermorelin | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2006 | Sermorelin | Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908. PMC2699646. PMID 18046908 | research article |
| 2003 | Sermorelin | Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14662999. PMID 14662999 | research article |
| 1997 | Sermorelin | Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in older men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141535. PMID 9141535 | research article |
| 1996 | Sermorelin | Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PM… PMID 8772599 | research article |
| 1992 | Sermorelin | Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256. PMID 1379256 | research article |
| 1992 | Sermorelin | Duck SC, Schwarz HP, Costin G, et al. Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. J Clin Endocrinol Metab. 1992;75(4):1115-1120. PMID: 1400880. PMID 1400880 | research article |
| 1985 | Sermorelin | Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor. Evidence for intermittent somatostatin secretion. J Clin Invest. 1985;75(5):1584-1590. PMID: 2860118. PMID 2860118 | research article |
Related pair pages
More research context
Frequently asked
Have GHRP-2 and Sermorelin been studied together?
Researchers have published mechanistic-level co-administration discussion of GHRP-2 and Sermorelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do GHRP-2 and Sermorelin share?
GHRP-2 and Sermorelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of GHRP-2 and Sermorelin?
GHRP-2: Investigational (Category 2 bulk). Sermorelin: Approved 1997; discontinued 2008 (commercial). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on GHRP-2 and Sermorelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the GHRP-2 profile and the Sermorelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026